5985-38-6|Levorphanol tartrate (powder)|(4bR,8aR,9R)-11-methyl-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthren-3-ol (2S,3S)-2,3-dihydroxysuccinate dihydrate|-范德生物科技公司

Levorphanol tartrate (powder)

NMR下载 COA and HPLC MSDS下载
names：
(4bR,8aR,9R)-11-methyl-6,7,8,8a,9,10-hexahydro-5H-9,4b-(epiminoethano)phenanthren-3-ol (2S,3S)-2,3-dihydroxysuccinate dihydrate
CAS号：
5985-38-6
MDL Number：
MF(分子式)： C21H33NO9 MW(分子量)： 443.49
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Levorphanol tartrate (powder)
英文别名	Levorphanol tartrate; Levo-dromoran; Levorphanol D-tartrate dihydrate;
CAS号	5985-38-6
Inchi	InChI=1S/C17H23NO.C4H6O6.2H2O/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17;5-1(3(7)8)2(6)4(9)10;;/h5-6,11,14,16,19H,2-4,7-10H2,1H3;1-2,5-6H,(H,7,8)(H,9,10);2*1H2/t14-,16+,17+;1-,2-;;/m00../s1
InchiKey	UMZNDVASJKIQCB-ULFFVNIPSA-N
分子式 Formula	C21H33NO9
分子量 Molecular Weight	443.49
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Levorphanol tartrate (powder)(CAS:5985-38-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Levorphanol tartrate is a synthetic morphine analog that is a narcotic analgesic and μ opioid receptor agonist. Levorphanol tartrate (powder) is discontinued (DEA controlled substance).
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Comparison table: some oral/topical opioid analgesics. Med Lett Drugs Ther. 2018 Apr 9;60(1544):e64-e67. PubMed PMID: 29664447.

[2]Opioids for pain. Med Lett Drugs Ther. 2018 Apr 9;60(1544):57-64. PubMed PMID: 29664446.

[3] Le Rouzic V, Narayan A, Hunkle A, Marrone GF, Lu Z, Majumdar S, Xu J, Pan YX, Pasternak GW. Pharmacological Characterization of Levorphanol, a G-Protein Biased Opioid Analgesic. Anesth Analg. 2018 Apr 11. doi: 10.1213/ANE.0000000000003360. [Epub ahead of print] PubMed PMID: 29649035.

[4] Watson AR, Roberts A. Identifying Levorphanol Ingestion Using Urine Biomarkers in Health Care Patients. Pain Physician. 2018 Mar;21(2):E167-E171. PubMed PMID: 29565959.

[5] Reddy A, Ng A, Mallipeddi T, Bruera E. Levorphanol for Treatment of Intractable Neuropathic Pain in Cancer Patients. J Palliat Med. 2018 Mar;21(3):399-402. doi: 10.1089/jpm.2017.0475. Epub 2018 Jan 29. PubMed PMID: 29377758.

6: Els C, Jackson TD, Kunyk D, Lappi VG, Sonnenberg B, Hagtvedt R, Sharma S, Kolahdooz F, Straube S. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017 Oct 30;10:CD012509. doi: 10.1002/14651858.CD012509.pub2. Review. PubMed PMID: 29084357.7: Tran HQ, Chung YH, Shin EJ, Tran TV, Jeong JH, Jang CG, Nah SY, Yamada K, Nabeshima T, Kim HC. MK-801, but not naloxone, attenuates high-dose dextromethorphan-induced convulsive behavior: Possible involvement of the GluN2B receptor. Toxicol Appl Pharmacol. 2017 Nov 1;33

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开